Daclatasvir/peginterferon lambda-1a/ribavirin in patients with chronic HCV infection and haemophilia who are treatment naïve or prior relapsers to peginterferon alfa-2a/ribavirin

Haemophilia

Volumn 22, Issue 5, 2016, Pages 692-699

  Santagostino, E ^a   Pol, S ^b   Olveira, A ^c   Reesink, H W ^d   van Erpecum, K ^e   Bogomolov, P ^f   Xu, D ^g   Critelli, L ^g   Srinivasan, S ^g   Cooney, E ^g  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b Institut Cochin   (France)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f Clinical Hospital of Tsentrosoyuz   (Russian Federation)

^g BRISTOL MYERS SQUIBB   (United States)

Author keywords

daclatasvir; haemophilia; hepatitis C; peginterferon lambda 1a; ribavirin; sustained virologic response

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DACLATASVIR; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON LAMBDA; RIBAVIRIN;

ACUTE HEPATITIS; ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; ASTHENIA; BACTERIAL ARTHRITIS; CHRONIC HEPATITIS C; COMBINATION CHEMOTHERAPY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HEMOPHILIA; HEMORRHOID; HUMAN; HYPERTRANSAMINASEMIA; INSOMNIA; JAUNDICE; MALE; NAUSEA; PHASE 3 CLINICAL TRIAL; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RELAPSE;

EID: 84990199882     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12947     Document Type: Article

References (39)

1. Makris M, Garson JA, Ring CJ, Tuke PW, Tedder RS, Preston FE. Hepatitis C viral RNA in clotting factor concentrates and the development of hepatitis in recipients. Blood 1993; 81: 1898–902.
2. Assy N, Pettigrew N, Lee SS, Chaudhary RK, Johnston J, Minuk GY. Are chronic hepatitis C viral infections more benign in patients with hemophilia? Am J Gastroenterol 2007; 102: 1672–6.
3. Fransen van de Putte DE, Makris M, Fischer K et al. Long-term follow-up of hepatitis C infection in a large cohort of patients with inherited bleeding disorders. J Hepatol 2014; 60: 39–45.
4. Nelson DR, Cooper JN, Lalezari JP et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015; 61: 1127–35.
5. Manns M, Pol S, Jacobson IM et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 2014; 384: 1597–605.
6. Kumada H, Suzuki Y, Ikeda K et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 2014; 59: 2083–91.
7. Afdhal N, Reddy KR, Nelson DR et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483–93.
8. Afdhal N, Zeuzem S, Kwo P et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889–98.
9. Jacobson IM, Dore GJ, Foster GR et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014; 384: 403–13.
10. Manns M, Marcellin P, Poordad F et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014; 384: 414–26.
11. Santagostino E, De Filippi F, Rumi MG, Rivi M, Colombo M, Mannucci PM; Hepatitis Study Group of the Association of Italian Hemophilia Centers. Sustained suppression of hepatitis C virus by high doses of interferon and ribavirin in adult hemophilic patients. Transfusion 2004; 44: 790–4.
12. Katsarou O, Theodosiades G, Ioannidou P et al. Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C in patients with congenital coagulation disorders. Acta Haematol 2008; 120: 63–9.
13. Posthouwer D, Yee TT, Makris M et al. Antiviral therapy for chronic hepatitis C in patients with inherited bleeding disorders: an international, multicenter cohort study. J Thromb Haemost 2007; 5: 1624–9.
14. Mancuso ME, Rumi MG, Santagostino E et al. High efficacy of combined therapy with pegylated interferon plus ribavirin in patients with hemophilia and chronic hepatitis C. Haematologica 2006; 91: 1367–71.
15. Franchini M, Mengoli C, Veneri D, Mazzi R, Lippi G, Cruciani M. Treatment of chronic hepatitis C in haemophilic patients with interferon and ribavirin: a meta-analysis. J Antimicrob Chemother 2008; 61: 1191–200.
16. Alavian SM, Tabatabaei SV, Keshvari M et al. Peginterferon alpha-2a and ribavirin treatment of patients with haemophilia and hepatitis C virus infection: a single-centre study of 367 cases. Liver Int 2010; 30: 1173–80.
17. Fried MW, Peter J, Hoots K et al. Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirin. Hepatology 2002; 36(pt 1): 967–72.
18. Lin JA, Chen YC, Cheng SN et al. Peginterferon alfa-2a plus ribavirin for hemophilic patients with chronic hepatitis C virus infection in Taiwan. J Formos Med Assoc 2014; 113: 727–33.
19. Zhou Z, Hamming OJ, Ank N, Paludan SR, Nielsen AL, Hartmann R. Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J Virol 2007; 81: 7749–58.
20. Kotenko SV, Gallagher G, Baurin VV et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003; 4: 69–77.
21. Sheppard P, Kindsvogel W, Xu W et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003; 4: 63–8.
22. Dumoutier L, Tounsi A, Michiels T, Sommereyns C, Kotenko SV, Renauld JC. Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J Biol Chem 2004; 279: 32269–74.
23. Muir A, Jurkowski C, Cooney E et al. Safety profile of peginterferon lambda for treatment of chronic hepatitis B (CHB) or chronic hepatitis C (CHC): cross-study analysis of patients treated in three phase 2 studies. Poster 1103. Hepatology 2013; 58: 744A–5A.
24. Muir AJ, Arora S, Everson G et al. A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. J Hepatol 2014; 61: 1238–46.
25. Pol S, Ghalib RH, Rustgi VK et al. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, Phase 2a trial. Lancet Infect Dis 2012; 12: 671–7.
26. Everson GT, Sims KD, Rodriguez-Torres M et al. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology 2014; 146: 420–9.
27. Sulkowski MS, Gardiner DF, Rodriguez-Torres M et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370: 211–21.
28. Lok AS, Gardiner DF, Hézode C et al. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. J Hepatol 2014; 60: 490–9.
29. Poordad F, Sievert W, Mollison L et al. Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. JAMA 2015; 313: 1728–35.
30. Muir AJ, Poordad F, Lalezari J et al. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA 2015; 313: 1736–44.
31. Aghemo A, De Francesco R. Daclatasvir: a team player rather than a prima donna in the treatment of hepatitis C. Gut 2015; 64: 860–2.
32. Hézode C, Hirschfield GM, Ghesquiere W et al. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut 2015; 64: 948–56.
33. Bunchorntavakul C, Reddy KR. Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther 2015; 42: 258–72.
34. Rumi MG, Santagostino E, Morfini M et al. A multicenter controlled, randomized, open trial of interferon alpha2b treatment of anti-human immunodeficiency virus-negative hemophilic patients with chronic hepatitis C. Hepatitis Study Group of the Association of Italian Hemophilia Centers. Blood 1997; 89: 3529–33.
35. Zoulim F, Bailly F. New approaches to the management of hepatitis C in haemophilia in 2012. Haemophilia 2012; 18: 28–33.
36. Fransen van de Putte DE, Fischer K, Posthouwer D, Mauser-Bunschoten EP. The burden of HCV treatment in patients with inherited bleeding disorders. Haemophilia 2011; 17: 791–9.
37. Stedman CA, Hyland RH, Ding X, Pang PS, McHutchison JG, Gane EJ. Once daily ledipasvir/sofosbuvir fixed-dose combination with ribavirin in patients with inherited bleeding disorders and hepatitis C genotype 1 infection. Haemophilia 2015; 22: 214–7.
38. Foster GR, Pianko S, Cooper C et al. Sofosbuvir + peginterferon/ribavirin for 12 weeks vs sofosbuvir + ribavirin for 16 or 24 weeks in genotype 3 HCV infected patients and treatment-experienced cirrhotic patients with genotype 2 HCV: the BOSON study. J Hepatol 2015; 62: S259.
39. Pol S, Sulkowski MS, Hassanein T et al. Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct-acting antivirals has failed. Hepatology 2015; 62: 129–34.